Gotowa bibliografia na temat „Broadly neutralizing antibodies (bNAbs)”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Broadly neutralizing antibodies (bNAbs)”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Broadly neutralizing antibodies (bNAbs)"
Karuna, Shelly T., i Lawrence Corey. "Broadly Neutralizing Antibodies for HIV Prevention". Annual Review of Medicine 71, nr 1 (27.01.2020): 329–46. http://dx.doi.org/10.1146/annurev-med-110118-045506.
Pełny tekst źródłaYang, Guang, Mengfei Liu, Kevin Wiehe, Nathan Nicely, Barton Haynes, John Mascola, Pamela Bjorkman i Garnett Kelsoe. "HIV broadly neutralizing antibodies and immunological tolerance (VAC7P.988)". Journal of Immunology 192, nr 1_Supplement (1.05.2014): 141.33. http://dx.doi.org/10.4049/jimmunol.192.supp.141.33.
Pełny tekst źródłaLubow, Jay, Lisa M. Levoir, Duncan K. Ralph, Laura Belmont, Maya Contreras, Catiana H. Cartwright-Acar, Caroline Kikawa i in. "Single B cell transcriptomics identifies multiple isotypes of broadly neutralizing antibodies against flaviviruses". PLOS Pathogens 19, nr 10 (9.10.2023): e1011722. http://dx.doi.org/10.1371/journal.ppat.1011722.
Pełny tekst źródłaSprenger, Kayla G., Joy E. Louveau, Pranav M. Murugan i Arup K. Chakraborty. "Optimizing immunization protocols to elicit broadly neutralizing antibodies". Proceedings of the National Academy of Sciences 117, nr 33 (3.08.2020): 20077–87. http://dx.doi.org/10.1073/pnas.1919329117.
Pełny tekst źródłaGlazkova, D. V., E. V. Bogoslovskaya, G. A. Shipulin i S. M. Yudin. "Broadly neutralizing antibodies for the treatment of HIV infection". HIV Infection and Immunosuppressive Disorders 13, nr 3 (24.10.2021): 81–95. http://dx.doi.org/10.22328/2077-9828-2021-13-3-81-95.
Pełny tekst źródłaShrader, Hannah, Sabrina Helmold Hait, Sarah Lovelace, Meaghan Kilner, Chen-Hsiang Shen, Emily Coates, Martin Gaudinski i in. "Phenotypic analysis of HIV-1 resistance to CD4 binding site broadly-neutralizing antibodies". Journal of Immunology 210, nr 1_Supplement (1.05.2023): 223.08. http://dx.doi.org/10.4049/jimmunol.210.supp.223.08.
Pełny tekst źródłaSteichen, Jon M., Ying-Cing Lin, Colin Havenar-Daughton, Simone Pecetta, Gabriel Ozorowski, Jordan R. Willis, Laura Toy i in. "A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses". Science 366, nr 6470 (31.10.2019): eaax4380. http://dx.doi.org/10.1126/science.aax4380.
Pełny tekst źródłaThavarajah, Jannifer Jasmin, Bo Langhoff Hønge i Christian Morberg Wejse. "The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention". Viruses 16, nr 6 (4.06.2024): 911. http://dx.doi.org/10.3390/v16060911.
Pełny tekst źródłaKumar, Rajesh, Huma Qureshi, Suprit Deshpande i Jayanta Bhattacharya. "Broadly neutralizing antibodies in HIV-1 treatment and prevention". Therapeutic Advances in Vaccines and Immunotherapy 6, nr 4 (sierpień 2018): 61–68. http://dx.doi.org/10.1177/2515135518800689.
Pełny tekst źródłaXu, Ling, Amarendra Pegu, Ercole Rao, Nicole Doria-Rose, Jochen Beninga, Krisha McKee, Dana M. Lord i in. "Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques". Science 358, nr 6359 (20.09.2017): 85–90. http://dx.doi.org/10.1126/science.aan8630.
Pełny tekst źródłaRozprawy doktorskie na temat "Broadly neutralizing antibodies (bNAbs)"
Nemoz, Benjamin. "Exploration longitudinale à haut débit et en cellule unique du répertoire d'anticorps neutralisants à large spectre chez un neutraliseur d'élite du VIH-1". Electronic Thesis or Diss., Université Grenoble Alpes, 2024. http://www.theses.fr/2024GRALV012.
Pełny tekst źródłaHuman Immunodeficiency Virus type 1 (HIV-1) infection remains a major global health concern, with an estimated 37.7 million people living with the virus worldwide and new contaminations above a million cases yearly. Efficient anti-retroviral therapies are available, allowing a sustained relief for infected individuals. These therapeutics have also contributed to a better prevention and helped curb the epidemic, notably in high-income countries. However, a vaccine is still highly awaited for controlling this epidemic, especially in lower-income regions and precarious settings.The protective role of neutralizing antibodies (NAbs) has been unequivocally demonstrated in both animal models of HIV infection and in human settings. Consequently, the development of a B-cell-based vaccine capable of eliciting antibodies (Abs) with the ability to neutralize the majority of circulating viruses, namely broadly NAbs (bNAbs), could be foreseen as an answer to the HIV pandemic.The investigation of bNAb development in HIV-1 elite neutralizers provides valuable insights to inform the design of such vaccines. To date, most of the undertaken studies have relied on conventional single B-cell FACS sorting to isolate bNAbs. In the present study, we have used the Chromium Single Cell Immune Profiling approach to conduct a high-throughput longitudinal single-cell exploration of the B-cell repertoire in an HIV-1 elite neutralizer. Importantly, this novel method enables the use of a much greater number of HIV envelope glycoprotein (Env) baits compared to regular FACS-based Ab isolation studies, providing a more comprehensive view of the anti-Env Ab repertoire. In addition, this approach yields a wealth of information on the nature of the specific Abs identified and the corresponding B-cells.The study enabled the uncovering of the sequence of 12,130 putative HIV Env specific Abs. Antibodies from 39 lineages were produced and tested for neutralization, revealing 21 distinct neutralizing lineages. The results thus demonstrated the ability of the method to explore large antigen-specific Ab repertoires from longitudinal samples. The neutralizing activity of Abs from four neutralizing lineages together recapitulated the serum activity of the donor, achieving neutralization against 62.4 % of a large predictive panel of 126 pseudoviruses. One of these neutralizing Ab lineages was shown to target the gp120 high-mannose patch supersite with great breadth and potency; Abs from this lineage were sensitive to the presence of a glycan in position N332. A single of those Abs achieved most of the neutralization breadth (51.1 %) with a high potency (mean IC50 of 91.1 ng.mL-1). This Ab exhibited a 23 AA-long CDRH3 and 20 % somatic hypermutation (SMH). The lineage showed continuous evolution over 6.5 years of maturation, with observed SHM rates ranging from 2.0 % to 30.6 % for the heavy chain, without any insertions or deletions.Conventional FACS-based sorting was previously used to isolate bNAbs from the same donor. In comparison, the single cell high-throughput approach made possible the isolation of orders of magnitude more Abs. Furthermore, the newly isolated NAbs were overall more potent and broader than those isolated previously, indicating the superiority of the novel method in recovering neutralizing lineages. Ongoing structural studies will elucidate the epitopes responsible for the broad neutralization observed in this donor. Together, the findings may help the design of reverse vaccine approaches, which show promise in the development of an effective AIDS vaccine
Derby, Nina Rafterman. "Designing immunogens to elicit broadly reactive neutralizing antibodies to the HIV envelope /". Thesis, Connect to this title online; UW restricted, 2007. http://hdl.handle.net/1773/9302.
Pełny tekst źródłaPenn-Nicholson, Adam Garth. "Characterization and evaluation of approaches to elicit Broadly Reactive Neutralizing Antibodies against HIV-1". Case Western Reserve University School of Graduate Studies / OhioLINK, 2008. http://rave.ohiolink.edu/etdc/view?acc_num=case1205433621.
Pełny tekst źródłaSuphaphiphat, Karunasinee. "Anti-viral immune response in the semen of cynomolgus macaques and inhibition of cell to cell transmission by broadly neutralizing antibodies in an SIV/SHIV model of infection SHIV162P3 transmission by semen 1 leukocytes is efficiently 2 inhibited by broadly neutralizing antibodies". Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS599.
Pełny tekst źródłaHIV-1 sexual transmission occurs mostly through contaminated semen, which contains both free virions and infected leukocytes. Moreover, factors in seminal plasma (SP) can influence both semen infectivity and host’s response. Therefore, we used the experimental model of Simian Immunodeficiency Virus (SIV) infection of macaques, to investigate semen cells infectivity and the antiviral immune responses and to evaluate the potency of broadly neutralizing antibodies (bNAbs) to block cell-to-cell virus transmission.In SIVmac251 infected cynomolgus macaques, we investigated SIV-specific innate and adaptive responses in semen, including CD8+ T cell response, humoral response and levels of cytokines, chemokines and growth factors. SIV infection induced pro-inflammatory and immunoregulatory cytokines in semen and a concomitant upregulation of activated CD69+ CD8+ T cells and CCR5+ CXCR3+ CD8+ T cells. Neither SIV-specific CD8+ T-cell responses nor humoral responses controlled seminal viral shedding. Failure to control viral replication in SIV-infected semen is related to a general inflammation and immune activation, which possibly mirrors what happen in the male genital tract and which could lead to enhanced HIV/SIV transmission.Moreover, we developed cell-to-cell transmission assays, using either TZM-bl or human PBMC as target cells and SHIV162P3-infected splenocytes and CD45+ semen leukocytes as donor cells, and evaluated bNAbs-mediated inhibition. The bNAb panel included four 1st generation bNAbs and eight 2nd generation bNAbs. A combination of 1st generation bNAbs (2F5+2G12+4E10) was able to efficiently inhibit CAV transmission, while double combination or single bNAbs showed reduced potency. Of note, individual 2nd generation bNAbs inhibited transmission as efficiently as bNAbs combinations. An anti-V3 bNAb has been selected to evaluate its potential to block cell-to-cell transmission in vivo
Corti, Davide. "Analysis of the human B cell memory repertoire against infectious pathogens and isolation of broadly neutralizing human monoclonal antibodies /". Bern : [s.n.], 2008. http://www.ub.unibe.ch/content/bibliotheken_sammlungen/sondersammlungen/dissen_bestellformular/index_ger.html.
Pełny tekst źródłaYuan, Tingting, i 袁婷婷. "Identification of intermediate antibodies of broadly neutralizing HIV-1 human monoclonal antibody b12 and characterization of variable loops of HIV-1 envelop glycoprotein". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2013. http://hdl.handle.net/10722/196445.
Pełny tekst źródłaGardner, Matthew Ryan. "Targeting the CD4- and Coreceptor-Binding Sites of the HIV-1 Envelope Glycoprotein". Thesis, Harvard University, 2014. http://dissertations.umi.com/gsas.harvard:11644.
Pełny tekst źródłaCheng, Yuxing. "Elicitation of antibody responses against the HIV-1 gp41 Membrane Proximal External Region (MPER)". Thesis, Harvard University, 2014. http://dissertations.umi.com/gsas.harvard:11427.
Pełny tekst źródłaMiles, Brodie, Shannon M. Miller i Elizabeth Connick. "CD4 T Follicular Helper and Regulatory Cell Dynamics and Function in HIV Infection". FRONTIERS MEDIA SA, 2016. http://hdl.handle.net/10150/622733.
Pełny tekst źródłaHashem, Anwar. "Targeting the Highly Conserved Sequences in Influenza A Virus". Thèse, Université d'Ottawa / University of Ottawa, 2013. http://hdl.handle.net/10393/24058.
Pełny tekst źródłaKsiążki na temat "Broadly neutralizing antibodies (bNAbs)"
Cox, Josephine H., Stuart Z. Shapiro, Liza Dawson, Cynthia Geppert, Andrew M. Siegel i M. Patricia D’Souza. Vaccines for The Prevention and Treatment of HIV Infection. Redaktorzy Mary Ann Cohen, Jack M. Gorman, Jeffrey M. Jacobson, Paul Volberding i Scott Letendre. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199392742.003.0032.
Pełny tekst źródłaSchommers, Philipp, Harry Gristick, Marit J. Van Gils i Kshitij Wagh, red. Novel Concepts in Using Broadly Neutralizing Antibodies for HIV-1 Treatment and Prevention. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-88974-305-6.
Pełny tekst źródłaCzęści książek na temat "Broadly neutralizing antibodies (bNAbs)"
Wu, Xueling. "HIV Broadly Neutralizing Antibodies: VRC01 and Beyond". W HIV Vaccines and Cure, 53–72. Singapore: Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-13-0484-2_3.
Pełny tekst źródłaZhou, Tongqing, i Kai Xu. "Structural Features of Broadly Neutralizing Antibodies and Rational Design of Vaccine". W HIV Vaccines and Cure, 73–95. Singapore: Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-13-0484-2_4.
Pełny tekst źródłaPauthner, Matthias G., i Lars Hangartner. "Broadly Neutralizing Antibodies to Highly Antigenically Variable Viruses as Templates for Vaccine Design". W Current Topics in Microbiology and Immunology, 31–87. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/82_2020_221.
Pełny tekst źródłaZhang, Mei-Yun, i Dimiter S. Dimitrov. "Sequential Antigen Panning for Selection of Broadly Cross-Reactive HIV-1-Neutralizing Human Monoclonal Antibodies". W Methods in Molecular Biology, 143–54. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-302-2_11.
Pełny tekst źródłaVan Regenmortel, Marc H. V. "Why Does the Molecular Structure of Broadly Neutralizing Monoclonal Antibodies Isolated from Individuals Infected with HIV-1 Not Inform the Rational Design of an HIV-1 Vaccine?" W HIV/AIDS: Immunochemistry, Reductionism and Vaccine Design, 221–28. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-32459-9_19.
Pełny tekst źródłaMorris, L., i T. A. Moody. "Broadly Neutralizing Antibodies". W Human Vaccines, 3–21. Elsevier, 2017. http://dx.doi.org/10.1016/b978-0-12-802302-0.00012-1.
Pełny tekst źródłaMohamed, Yehia. "The Future of HIV Vaccine Development, Learned Lessons from COVID-19 Pandemic". W New Topics in Vaccine Development [Working Title]. IntechOpen, 2024. http://dx.doi.org/10.5772/intechopen.114355.
Pełny tekst źródłaNi, Fengyun, i Qinghua Wang. "Stem-specific Broadly Neutralizing Antibodies of Influenza Virus Hemagglutinin". W Influenza: Current Research, 1–16. Caister Academic Press, 2016. http://dx.doi.org/10.21775/9781910190432.01.
Pełny tekst źródłaHaynes, Barton F., Kevin O. Saunders, Garnett Kelsoe, John R. Mascola i Gary J. Nabel. "The Cellular and Molecular Biology of HIV-1 Broadly Neutralizing Antibodies". W Molecular Biology of B Cells, 441–61. Elsevier, 2015. http://dx.doi.org/10.1016/b978-0-12-397933-9.00024-2.
Pełny tekst źródłaMallard, Bonnie, Mehdi Emam, Shannon Cartwright, Tess Altvater-Hughes, Alexandra Livernois, Lauri Wagter-Lesperance, Douglas C. Hodgins i in. "Advances in understanding immune response in dairy cattle". W Improving dairy herd health Improving, 121–62. Burleigh Dodds Science Publishing, 2021. http://dx.doi.org/10.19103/as.2020.0086.06.
Pełny tekst źródłaStreszczenia konferencji na temat "Broadly neutralizing antibodies (bNAbs)"
Morton, Scott P., i Joshua L. Phillips. "pH Dependent Binding Energies of Broadly Neutralizing Antibodies". W 2021 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). IEEE, 2021. http://dx.doi.org/10.1109/bibm52615.2021.9669511.
Pełny tekst źródłaSolodkov, P. P., T. N. Belovezhets, A. N. Chikaev, K. O. Baranov, S. V. Kulemzin, A. A. Gorchakov, S. V. Guselnikov i in. "SINGLE DOMAIN LLAMA ANTIBODIES BROADLY NEUTRALIZING SARS-COV-2 VARIANTS". W X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-127.
Pełny tekst źródłaFlyak, Andrew I., Stormy Ruiz, Michelle Colbert, Tiffany Luong, James E. Crowe, Justin R. Bailey i Pamela J. Bjorkman. "Abstract B109: Broadly neutralizing antibodies against HCV use a CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design". W Abstracts: Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 30 - October 3, 2018; New York, NY. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/2326-6074.cricimteatiaacr18-b109.
Pełny tekst źródła